Dr. Ankur Bahl is a highly skilled cancer specialist with more than 15 years of experience in the field of Medical Oncology. Currently serving as Principal Director of Medical Oncology at Fortis Gurgaon, he brings extensive clinical expertise in chemotherapy, immunotherapy, targeted therapies, hormonal therapy, supportive care, and palliative care. His deep commitment to evidence-based cancer treatment makes him a trusted choice for patients seeking comprehensive oncological care.
Dr. Bahl is an alumnus of Maulana Azad Medical College, Delhi, where he completed his MBBS, followed by an MD in Medicine. He further pursued his DM in Medical Oncology from the prestigious AIIMS, New Delhi, and has completed a specialized course on Adverse Drug Reactions, Drug Interactions, and Pharma Covigilance at the University of Oxford, UK.
He is recognized as the lead author of the largest real-world Indian data on targeted therapy (Cetuximab) in head and neck cancer, acute myeloid leukaemia treatment, and Human Papilloma Virus trends in the Indian population.
- Medical Oncology
- Chemotherapy (per cycle)
- Chemotherapy for Solid Tumors
- Adjuvant Chemotherapy
- Neoadjuvant Chemotherapy
- Palliative Chemotherapy
- Immunotherapy for Advanced Cancer
- Immunotherapy for Solid Tumors
- Immune Checkpoint Inhibitor Therapy
- Targeted Therapy for Solid Tumor Cancers
- Biomarker-Based Targeted Therapy
- Hormone Therapy for Breast Cancer
- Molecular Targeted Therapy
- MBBS — Maulana Azad Medical College, Delhi
- MD (Medicine) — Maulana Azad Medical College, Delhi
- DM (Medical Oncology) — All India Institute of Medical Sciences (AIIMS), New Delhi
- Course on Adverse Drug Reactions, Drug Interactions, and Pharma Covigilance — University of Oxford, UK
- Fortis Memorial Research Institute (FMRI), Gurugram (Current)
- Max Hospital, Saket (Previous — Director, Medical Oncology and Haematology Oncology)
- Rajiv Gandhi Cancer Institute and Research Centre (Previous)
- Maulana Azad Medical College (Previous)
- Lead author of the largest real-world Indian data on targeted therapy (Cetuximab) in head and neck cancer, acute myeloid leukaemia treatment, and Human Papilloma Virus trends in the Indian population
- Innumerable publications in international and national journals and books of repute
- Lead founder of various innovative oncology educational platforms and networks (international and national)
- Advisor to various biopharmaceutical research and development organizations
- Professional guide to various international and national medical oncology fellows and students
- Led various NGOs for "No Tobacco" workshops for teens in Delhi schools
- Active contributor to evidence-based debates in oncology, live oncology tumour boards, master classes, and workshops in oncology
From your first enquiry to recovery back home — we manage every detail so you can focus on getting better.
Join 5,000+ patients from 40+ countries who chose world-class care at a fraction of the cost.
